Home » Topics » BioWorld Science

BioWorld Science
RSS

New global phase IIa study evaluates tezepelumab for moderate to very severe COPD

Aug. 27, 2019

Basilea completes enrollment in phase I study of oral BAL-101553 in brain cancer

Aug. 27, 2019

DNA's sweet tooth linked to increased cancer risk with diabetes

Aug. 27, 2019

Ivy, Salarius Pharmaceuticals enter collaboration to develop new cancer treatment for glioblastoma

Aug. 27, 2019

Ubiquitin carboxyl-terminal hydrolase 19 inhibitors discovered at Almac Discovery

Aug. 27, 2019

Janssen presents respiratory syncytial virus replication inhibitors

Aug. 27, 2019

Heparegenix synthesizes new MAPKK 4 inhibitors

Aug. 27, 2019

New lysosomal acid glucosylceramidase inhibitors identified at Takeda

Aug. 27, 2019

Esteve Pharmaceuticals describes dual CACNA2D1/mu opioid receptor ligands

Aug. 27, 2019

IL-2-R336A fusion toxin enhances antitumor immune response in preclinical models

Aug. 27, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 4, 2026.
University of Western Australia patents 5-HT2A/B modulators
BioWorld Science
University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...
Alceptor Therapeutics discovers new α2B-adrenoceptor agonists
BioWorld Science
Alceptor Therapeutics Inc. has patented new pyrazol-5-amine α2B-adrenoceptor agonists reported to be useful for the treatment of pain and hypertension.
EQ-504 is AhR agonist for ulcerative colitis, related disorders
BioWorld Science
Activating the aryl hydrocarbon receptor (AhR) in immune cells enhances anti-inflammatory pathways and limits pathogenic immune responses. Equillium Inc. has...
Quintuple GLP-1–GIP–PPAR agonist for obesity and diabetes control
BioWorld
A new molecule combines the action of two incretins, GLP-1 and GIP, hormones that regulate glucose and appetite, with lanifibranor, a triple agonist of peroxisome...